Steroid use during pregnancy

Journal of Perinatal and Neonatal Nursing

Volumn 16, Issue 2, 2002, Pages 26-39

  McGee, Deborah Cooper ^a,b  

^a Obstetrix Medical Group of Colorado   (United States)

^b REGIS UNIVERSITY   (United States)

Author keywords

Betamethasone; Corticosteroids; Dexamethasone; Fetus; Pregnancy

Indexed keywords

ANTIINFLAMMATORY AGENT; CORTICOSTEROID; GLUCOCORTICOID; STEROID;

DRUG EFFECT; FEMALE; FETOMATERNAL TRANSFUSION; HUMAN; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; REVIEW; RISK FACTOR; WOMEN'S HEALTH;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; FEMALE; GLUCOCORTICOIDS; HUMANS; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RISK FACTORS; STEROIDS; WOMEN'S HEALTH;

EID: 0036715616     PISSN: 08932190     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005237-200209000-00004     Document Type: Article

References (63)

1. Coustan DR, Mochizuki TK. Handbook for Prescribing Medications during Pregnancy. 3rd ed. Philadelphia: Lippincott-Raven; 1998.
2. Larimore WL, Petrie KA. Drug use during pregnancy and lactation. Prim Care. 2000;27(1):35-53.
3. Wendel PJ. Asthma in pregnancy. Obstet Gynecol Clin. 2001;28(3):537-551.
4. Centers for Disease Control and Prevention. Preterm singleton births - United States, 1989-1996. MMWR Morb Mortal Wkly Rep. 1999;48(9):185-189.
5. National Center for Health Statistics. Birth weight and gestation. Nat Vital Stat Rep. 1999;49(1):15-16.
6. Vermillion ST, Soper DE, Chasedunnq J. Neonatal sepsis after betamethasone administration to patients with preterm premature rupture of membranes. Am J Obstet Gynecol. 1999;181(2):320-327.
7. National Institutes of Health Consensus Development Panel Conference Statement. Effects of corticosteroids for fetal maturation on perinatal outcome. JAMA. 1995;273:413-417.
8. American College of Obstetricians and Gynecologists. ACOG Committee Opinion #210: Antenatal Corticosteroid Administration Therapy for Fetal Maturation. Washington, DC: ACOG; 1998.
9. National Institutes of Health Consensus Development Panel. Antenatal corticosteroids revisited: repeat courses - National Institutes of Health Consensus Development Conference Statement, August 17-18, 2000. Obstet Gynecol. 2001;98(1):144-150.
10. Helal KJ, Gordon MC, Lightner CR, Barth WH. Adrenal suppression induced by betamethasone in women at risk for premature delivery. Obstet Gynecol. 2000;96(2): 287-290.
11. Shelton SD, Boggess KA, Murtha AP, Groff AO, Herbert WN. Repeated fetal betamethasone treatment and birth weight and head circumference. Obstet Gynecol. 2001;97(2):301-304.
12. McEvoy C, Bowling S, Williamson K, Collins J, Tolaymat L, Maher J. Timing of antenatal corticosteroids and neonatal pulmonary mechanics. Am J Obstet Gynecol. 2000;183(4):895-899.
13. Canterino JC, Verma U, Visintainer PF, Elimian A, Klein SA, Tejani N. Antenatal steroids and neonatal periventricular leukomalacia. Obstet Gynecol. 2001;97(1): 135-146.
14. Baud O, Foix-L'Helias L, Kaminski M, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med. 1999; 341(16):1190-1196.
15. Pattinson RC, Makin JD, Funk M, et al. The use of dexamethasone in women with preterm premature rupture of membranes: a multicentre, double-blinded, placebo-controlled, randomized trial. Dexiprom study group. S Afr Med J. 1999;89(3):850-851.
16. Vermillion ST, Soper DE, Bland ML, Newman RB. Effectiveness of antenatal corticosteroid administration after preterm premature rupture of membranes. Am J Obstet Gynecol. 2000;183(4):925-929.
17. Lo JC, Grumbach MM. Pregnancy outcomes in women with congenital virilizing adrenal hyperplasia. Endocrinol Metab Clin North Am. 2001;30(1):207-229.
18. Samuels P. Collegen vascular diseases. In: Gabbe SG, Niebyl JR, Simpson JL, eds. Obstetrics: Normal and Problem Pregnancies. 3rd ed. Philadelphia: Churchill Livingstone; 1996.
19. Vermillion ST, Soper DE, Newman RB. Is betamethasone effective longer than 7 days after treatment? Obstet Gynecol. 2001;97(4):491-493.
20. O'Boyle JD, Magann EF, Waxman E, Martin JN Jr. Dexamethasone-facilitated postponement of delivery of an extremely preterm pregnancy complicated by the syndrome of hemolysis, elevated liver enzymes, and low platelets. Mil Med. 1999;164(4):316-318.
21. Schlembach D, Munz W, Fischer T. Effect of corticosteroids on HELLP syndrome: a case report. J Perinat Med. 2000;28(6):502-505.
22. Tompkins MJ, Thigarajah S. HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: the benefit of corticosteroids. Am J Obstet Gynecol. 1999; 181(2):304-309.
23. Isler CM, Barrilleaux PS, Magann EF, Bass JD, Martin JN Jr. A prospective, randomized trial comparing the efficacy of dexamethasone and betamethasone for the treatment of antepartum HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol. 2001;184(7):1332-1337.
24. Magann EF, Martin JN Jr. Critical care of HELLP syndrome with corticosteroids. Am J Perinatol. 2001;17(8):417-422.
25. O'Brien JM, Milligan DA, Barton JR. Impact of high-dose corticosteroid therapy for patients with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol. 2000;183(4):921-924.
26. Nelson-Piercy C, Payers P, de Swiet M. Randomised, double-blinded, placebo-controlled trial of corticosteroids for the treatment of hyperemesis gravidarum. Br J Obstet Gynaecol. 2001;108(1):9-15.
27. Safari HR, Alsulyman OM, Gherman RB, Goodwin TM. Experience with oral methylprednisolone in the treatment of refractory hyperemesis gravidarum. Am J Obstet Gynecol. 1998;178(5):1054-1058.
28. Safari HR, Fassett MJ, Souter IC, Alsulyman OM, Goodman TM. The efficacy of methylprednisolone in the treatment of hyperemesis gravidarum: a randomized, double-blind, controlled study. Am J Obstet Gynecol. 1998;179(4):921-924.
29. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2002.
30. Robson SC. Fetal endocrinology. In: James DK, Steer PJ, Weiner CP, Gonik B, eds. High Risk Pregnancy: Management Options. Philadelphia: W.B. Saunders; 1999.
31. Nader S. Other endocrine disorders of pregnancy. In: Creasy RK, Resnik R, eds. Maternal Fetal Medicine. Philadelphia: W.B. Saunders; 1999.
32. Harman CR. Percutaneous fetal blood sampling. In: Creasy RK, Resnik R, eds. Maternal Fetal Medicine. 4th ed. Philadelphia: W.B. Saunders; 1999.
33. Radoncic E, Delmis J, Pfeifer D, Mayer D. Successful treatment of alloimmune thrombocytopenia using corticosteroid therapy in women with two consecutive neonatal deaths - case report. Acta Med Croatica. 2000;54(3):125-127.
34. Whittle MJ. Fetal thrombocytopenia. In: James DK, Steer PJ, Weiner CP, Gonik B, eds. High Risk Pregnancy: Management Options. 2nd ed. Philadelphia: W.B. Saunders; 1999.
35. Rosenthal D, Druzin M, Chin C, Dubin A. A new therapeutic approach to the fetus with congenital complete heart block: preemptive, targeted therapy with dexamethasone. Obstet Gynecol. 1998;92(4. pt 2):689-691.
36. Theander E, Brucato A, Gudmundsson S, Salomonsson S, Wahren-Herlenius M, Manthorpe R. Primary Sjogren's syndrome - treatment of fetal incomplete atrioventricular block with dexamethasone. J Rheumatol. 2001;28(2):373-376.
37. Gladman DD, Urowitz MB. Rheumatic disease in pregnancy. In: Burrow GN, Duffy TP, eds. Medical Complications in Pregnancy. 5th ed. Philadelphia: W.B. Saunders; 1999.
38. Dizon-Townsend D. Immunologic disorders. In: American College of Obstetricians and Gynecologists. Precis: An Update in Obstetrics and Gynecology. Washington, DC: ACOG; 2000.
39. Duffy TP. Hematologic aspects of pregnancy. In: Burrow GN, Duffy TP, eds. Medical Complications in Pregnancy. 5th ed. Philadelphia: W.B. Saunders; 1999.
40. Aaronson DW. Medical-legal aspects of prescribing during pregnancy. Immunol Allergy Clin North Am. 2000;(20)4:699-714.
41. Garner PR. Pituitary and adrenal disorders. In: Burrow GN, Duffy TP, eds. Medical Complications in Pregnancy. 5th ed. Philadelphia: W.B. Saunders; 1999.
42. Chanco Turner ML. The skin in pregnancy. In: Burrow GN, Duffy TP, eds. Medical Complications in Pregnancy. 5th ed. Philadelphia: W.B. Saunders; 1999.
43. Dunn CL. Dermatologic disease. In: American College of Obstetricians and Gynecologists. Precis: An Update in Obstetrics and Gynecology. Washington, DC: ACOG; 2000.
44. Gordon MC, Landon MB. Dermatologic disorders. In: Gabbe SG, Niebyl JR, Simpson JL, eds. Obstetrics: Normal and Problem Pregnancies. 3rd ed. Philadelphia: Churchill Livingstone; 1996.
45. Nolan TE. Medical complications. In: American College of Obstetricians and Gynecologists. Precis: An Update in Obstetrics and Gynecology. Washington, DC: ACOG; 2000.
46. Scott LD. Gastrointestinal disease in pregnancy. In: Creasy RK, Resnik R, eds. Maternal Fetal Medicine. Philadelphia: W.B. Saunders; 1999.
47. Lockshin MD, Sammaritano LR. Corticosteroids during pregnancy. Scand J Rheumatol Suppl. 1998;107:136-138.
48. Silver RM, Branch DW. Immunologic disorders. In: Creasy RK, Resnik R, eds. Maternal Fetal Medicine. Philadelphia: W.B. Saunders; 1999.
49. Gutierrez K. Adrenal cortex drugs and inhibitors. In: Pharmacotherapeutics: Clinical Decision-Making in Nursing. Philadelphia: W.B. Saunders; 1999.
50. De Swiet M. Rheumatologic and connective tissue disorders. In: Creasy RK, Resnik R, eds. Maternal Fetal Medicine. Philadelphia: W.B. Saunders; 1999.
51. Lawson EL. Antenatal corticosteroids-too much of a good thing? JAMA. 2001; 286(13):1628-1630.
52. Bloom SL, Sheffield JS, McIntire DD, Leveno KJ. Antenatal dexamethasone and decreased birth weight. Obstet Gynecol. 2001;97(4):485-490.
53. Goldenberg RL, Wright LL. Repeated courses of antenatal corticosteroids. Obstet Gynecol. 2001;97(2):316-317.
54. Guinn DA, Atkinson MW, Sullivan L, et al. Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery: a randomized controlled trial. JAMA. 2001;286(13):1581-1587.
55. French NP, Hagan R, Evans SF, Godfrey M, Newnham NP. Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol 1999;180(1, pt 1):114-121.
56. Doyle LW, Ford GW, Rickards AL, et al. Antenatal corticosteroids and outcome at 14 years of age in children with birth weight less than 1501 grams. Pediatrics. 2000;106(1):E2.
57. Derks JB, Mulder EJ, Visser GH. The effects of maternal betamethasone administration on the fetus. Br J Obstet Gynaecol. 1995;102(1):40-46.
58. Mulder EJ, Derks JB, Zonnenveld MF, Bruinse HW, Visser GH. Transient reduction in fetal activity and heart rate variation after maternal betamethasone administration. Early Hum Dev. 1994;36(1):49-60.
59. Rotmensch S, Liberati M, Vishne TH, Celentano C, Ben-Rafael Z, Bellati U. The effects of betamethasone and dexamethasone on fetal heart rate patterns and biophysical activities. A prospective randomized trial. Acta Obstet Gynecol Scand. 1999;78(6):493-500.
60. Kelly MK, Schneider EP, Petrikovsky BM, Lesser ML. Effect of antenatal steroid administration on the fetal biophysical profile. J Clin Ultrasound. 2000;28(5):224-226.
61. Senat MV, Ville Y. Effect of steroids on arterial Doppler in intrauterine growth retardation fetuses. Fetal Diagn Ther. 2000;15(1):36-40.
62. Eliakim R, Abulafia O, Sherer DM. Hyperemesis gravidarum: a current review. Am J Perinatol. 2000;17(4):207-218.
63. Branch DW, Porter FT. Autoimmune disease. In: James DK, Steer PJ, Weiner CP, Gonik B, eds. High Risk Pregnancy: Management Options. 2nd ed. Philadelphia: W.B. Saunders; 1999.